216 related articles for article (PubMed ID: 27113165)
1. Characterization of serum antibodies from women immunized with Gardasil: A study of HPV-18 infection of primary human keratinocytes.
Wang HK; Wei Q; Moldoveanu Z; Huh WK; Vu HL; Broker TR; Mestecky J; Chow LT
Vaccine; 2016 Jun; 34(27):3171-3177. PubMed ID: 27113165
[TBL] [Abstract][Full Text] [Related]
2. Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions.
Smith JF; Brownlow M; Brown M; Kowalski R; Esser MT; Ruiz W; Barr E; Brown DR; Bryan JT
Hum Vaccin; 2007; 3(4):109-15. PubMed ID: 17611417
[TBL] [Abstract][Full Text] [Related]
3. Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines.
Jagu S; Karanam B; Gambhira R; Chivukula SV; Chaganti RJ; Lowy DR; Schiller JT; Roden RB
J Natl Cancer Inst; 2009 Jun; 101(11):782-92. PubMed ID: 19470949
[TBL] [Abstract][Full Text] [Related]
4. A novel candidate HPV vaccine: MS2 phage VLP displaying a tandem HPV L2 peptide offers similar protection in mice to Gardasil-9.
Zhai L; Peabody J; Pang YS; Schiller J; Chackerian B; Tumban E
Antiviral Res; 2017 Nov; 147():116-123. PubMed ID: 28939477
[TBL] [Abstract][Full Text] [Related]
5. Measurement of neutralizing serum antibodies of patients vaccinated with human papillomavirus L1 or L2-based immunogens using furin-cleaved HPV Pseudovirions.
Wang JW; Jagu S; Wang C; Kitchener HC; Daayana S; Stern PL; Pang S; Day PM; Huh WK; Roden RB
PLoS One; 2014; 9(7):e101576. PubMed ID: 24999962
[TBL] [Abstract][Full Text] [Related]
6. A randomized, observer-blinded immunogenicity trial of Cervarix(®) and Gardasil(®) Human Papillomavirus vaccines in 12-15 year old girls.
Draper E; Bissett SL; Howell-Jones R; Waight P; Soldan K; Jit M; Andrews N; Miller E; Beddows S
PLoS One; 2013; 8(5):e61825. PubMed ID: 23650505
[TBL] [Abstract][Full Text] [Related]
7. Roles of Fc Domain and Exudation in L2 Antibody-Mediated Protection against Human Papillomavirus.
Wang JW; Wu WH; Huang TC; Wong M; Kwak K; Ozato K; Hung CF; Roden RBS
J Virol; 2018 Aug; 92(15):. PubMed ID: 29743371
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years.
Einstein MH; Baron M; Levin MJ; Chatterjee A; Edwards RP; Zepp F; Carletti I; Dessy FJ; Trofa AF; Schuind A; Dubin G;
Hum Vaccin; 2009 Oct; 5(10):705-19. PubMed ID: 19684472
[TBL] [Abstract][Full Text] [Related]
9. Human papillomavirus type 11 neutralization in the athymic mouse xenograft system: correlation with virus-like particle IgG concentration.
Bryan JT; Jansen KU; Lowe RS; Fife KH; McClowry T; Glass D; Brown DR
J Med Virol; 1997 Nov; 53(3):185-8. PubMed ID: 9365880
[TBL] [Abstract][Full Text] [Related]
10. Human Papillomavirus neutralizing and cross-reactive antibodies induced in HIV-positive subjects after vaccination with quadrivalent and bivalent HPV vaccines.
Faust H; Toft L; Sehr P; Müller M; Bonde J; Forslund O; Østergaard L; Tolstrup M; Dillner J
Vaccine; 2016 Mar; 34(13):1559-1565. PubMed ID: 26896686
[TBL] [Abstract][Full Text] [Related]
11. The humoral response to Gardasil over four years as defined by total IgG and competitive Luminex immunoassay.
Brown DR; Garland SM; Ferris DG; Joura E; Steben M; James M; Radley D; Vuocolo S; Garner EI; Haupt RM; Bryan JT
Hum Vaccin; 2011 Feb; 7(2):230-8. PubMed ID: 21307649
[TBL] [Abstract][Full Text] [Related]
12. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.
McCormack PL; Joura EA
BioDrugs; 2011 Oct; 25(5):339-43. PubMed ID: 21942919
[TBL] [Abstract][Full Text] [Related]
13. Neutralizing and cross-neutralizing antibody titres induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programmes.
Barzon L; Squarzon L; Masiero S; Pacenti M; Marcati G; Mantelli B; Gabrielli L; Pascucci MG; Lazzarotto T; Caputo A; Palù G
Vaccine; 2014 Sep; 32(41):5357-62. PubMed ID: 25045814
[TBL] [Abstract][Full Text] [Related]
14. Multivalent human papillomavirus l1 DNA vaccination utilizing electroporation.
Kwak K; Jiang R; Jagu S; Wang JW; Wang C; Christensen ND; Roden RB
PLoS One; 2013; 8(3):e60507. PubMed ID: 23536912
[TBL] [Abstract][Full Text] [Related]
15. Durability of the neutralizing antibody response to vaccine and non-vaccine HPV types 7 years following immunization with either Cervarix® or Gardasil® vaccine.
Godi A; Panwar K; Haque M; Cocuzza CE; Andrews N; Southern J; Turner P; Miller E; Beddows S
Vaccine; 2019 Apr; 37(18):2455-2462. PubMed ID: 30926298
[TBL] [Abstract][Full Text] [Related]
16. Evolution of type-specific immunoassays to evaluate the functional immune response to Gardasil: a vaccine for human papillomavirus types 16, 18, 6 and 11.
Smith JF; Kowalski R; Esser MT; Brown MJ; Bryan JT
Hum Vaccin; 2008; 4(2):134-42. PubMed ID: 18388490
[TBL] [Abstract][Full Text] [Related]
17. Neutralization of human papillomavirus (HPV) pseudovirions: a novel and efficient approach to detect and characterize HPV neutralizing antibodies.
Yeager MD; Aste-Amezaga M; Brown DR; Martin MM; Shah MJ; Cook JC; Christensen ND; Ackerson C; Lowe RS; Smith JF; Keller P; Jansen KU
Virology; 2000 Dec; 278(2):570-7. PubMed ID: 11118379
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the immunogenicity and reactogenicity of Cervarix and Gardasil human papillomavirus vaccines in HIV-infected adults: a randomized, double-blind clinical trial.
Toft L; Storgaard M; Müller M; Sehr P; Bonde J; Tolstrup M; Østergaard L; Søgaard OS
J Infect Dis; 2014 Apr; 209(8):1165-73. PubMed ID: 24273179
[TBL] [Abstract][Full Text] [Related]
19. Human papillomavirus type 31b infection of human keratinocytes does not require heparan sulfate.
Patterson NA; Smith JL; Ozbun MA
J Virol; 2005 Jun; 79(11):6838-47. PubMed ID: 15890923
[TBL] [Abstract][Full Text] [Related]
20. Serum and cervicovaginal IgG immune responses against α7 and α9 HPV in non-vaccinated women at risk for cervical cancer: Implication for catch-up prophylactic HPV vaccination.
Mboumba Bouassa RS; Péré H; Gubavu C; Prazuck T; Jenabian MA; Veyer D; Meye JF; Touzé A; Bélec L
PLoS One; 2020; 15(5):e0233084. PubMed ID: 32421735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
